{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:41:52Z","timestamp":1787168512169,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica International Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofhospitalinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hospital Infection"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jhin.2018.11.003","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T02:17:59Z","timestamp":1541816279000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016"],"prefix":"10.1016","volume":"101","author":[{"given":"S.M.","family":"Heimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.G.T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gr\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Silling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhin.2018.11.003_bib1","series-title":"Isavuconazonium sulfate for the treatment of mucormycosis","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.jhin.2018.11.003_bib2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3201\/eid1509.090334","article-title":"Increasing incidence of zygomycosis (mucormycosis), France, 1997\u20132006","volume":"15","author":"Bitar","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3201\/eid1609.100276","article-title":"Increasing incidence of mucormycosis in University Hospital, Belgium","volume":"16","author":"Saegeman","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhin.2018.11.003_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.jhin.2018.11.003_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhin.2018.11.003_bib9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case\u2013control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib10","doi-asserted-by":"crossref","first-page":"O336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhin.2018.11.003_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1471-2334-14-310","article-title":"Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data","volume":"14","author":"Zilberberg","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2146\/ajhp080325","article-title":"Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients","volume":"66","author":"Menzin","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jhin.2018.11.003_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12879-016-2023-z","article-title":"Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study","volume":"16","author":"Kontoyiannis","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/myc.12631","article-title":"FungiScope \u2013 Global Emerging Fungal Infection Registry","volume":"60","author":"Seidel","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.jhin.2018.11.003_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Ruping","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhin.2018.11.003_bib17","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jhin.2018.11.003_bib18","series-title":"General methods for health economic evaluation","year":"2015"},{"key":"10.1016\/j.jhin.2018.11.003_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1524-4733.2007.00301.x","article-title":"German recommendations on health economic evaluation: third and updated version of the Hanover Consensus","volume":"11","author":"Graf von der Schulenburg","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jhin.2018.11.003_bib20","unstructured":"Institute for the Hospital Remuration System \u2013 InEK GmbH, The G-DRG report-browser. Bonn. Available at: http:\/\/www.g-drg.de\/cms\/Archiv2011."},{"key":"10.1016\/j.jhin.2018.11.003_bib21","series-title":"Microcosting methods for determining VA healthcare costs","author":"Smith","year":"2010"},{"key":"10.1016\/j.jhin.2018.11.003_bib22","series-title":"Generalized linear models and extensions","author":"Hardin","year":"2018"},{"key":"10.1016\/j.jhin.2018.11.003_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-014-2230-8","article-title":"Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole","volume":"34","author":"Heimann","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jhin.2018.11.003_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1439-0507.2012.02193.x","article-title":"Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals","volume":"55","author":"Rieger","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.jhin.2018.11.003_bib25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhin.2018.11.003_bib26","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Hospital Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670118305899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670118305899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:13:47Z","timestamp":1759292027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195670118305899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0195670118305899"],"URL":"https:\/\/doi.org\/10.1016\/j.jhin.2018.11.003","relation":{},"ISSN":["0195-6701"],"issn-type":[{"value":"0195-6701","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Hospital Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhin.2018.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}